Topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.
Gilead Sciences Inc. said on April 12 that the company decided to stop a late-stage trial of the intravenous treatment Veklury in high-risk non-hospitalized patients with Covid-19.
Immunosuppressive drugs for inflammatory diseases like rheumatoid arthritis, multiple sclerosis and ulcerative colitis can impair the body’s response to the Covid-19 vaccines from Pfizer/BioNTech and Moderna, according to new data.
Six months after a Covid-19 diagnosis, more than 33 percent of people exhibited some form of brain damage, according to a study appearing in Lancet Psychiatry.
Regeneron Pharmaceuticals announced results from the company’s Phase III trial of recently infected asymptomatic Covid-19 patients for the REGEN-COV (casirivimab with imdevimab) antibody cocktail.
AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized Covid-19 patients at serious risk of developing complications.
Treating Covid-19 patients at home with a commonly used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on April 12 which doctors said could change the way the disease is treated around the world.
Eli Lilly said on April 12 the company had a revised agreement with the U.S. government for the Covid-19 antibody drug bamlanivimab, which will now be sold in combination with another therapy.
While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
A follow-up study of 33 people who received Moderna Inc.’s Covid-19 vaccine in early trials show the antibodies it induced are still present six months after the second dose.
